The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset
about
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesIs lipid signaling through cannabinoid 2 receptors part of a protective system?Cannabinoids in health and diseaseThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarinEmerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammationSpecies-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersA comprehensive review of amyotrophic lateral sclerosisComplementary and Alternative Therapies in Amyotrophic Lateral SclerosisMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationThe role of endocannabinoids system in fatty liver disease and therapeutic potentialsTherapeutic neuroprotective agents for amyotrophic lateral sclerosisTargeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative DisordersBrain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis.The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?Cannabinoid control of neuroinflammation related to multiple sclerosis.Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDSProtective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy.Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonistInvestigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach.Modulating the endocannabinoid system in human health and disease--successes and failuresHuman metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis.Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.Targeting the endocannabinoid system: to enhance or reduce?Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond.Emerging strategies for exploiting cannabinoid receptor agonists as medicines.Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.Renal effects of chronic pharmacological manipulation of CB2 receptors in rats with diet-induced obesity.Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.ALSUntangled No. 16: cannabis.The endocannabinoid system: a putative role in neurodegenerative diseases.Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses.Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.
P2860
Q24623282-C29EE504-2D6B-40D7-91F1-57DEE4DAB609Q24633122-CFB20436-E595-42C9-B537-894B7B675152Q24633884-4A052504-19CA-42FE-8C32-9B884062D66CQ24643876-F4D9EE23-A482-4815-9354-B89E6344FFD3Q24647850-754365D9-9C66-421B-8FDE-5BB57C819662Q24673335-CD59995F-43B7-4625-A290-AE7A08DD2608Q26775401-5B874F67-33B8-4DF7-B1D3-ABA2EE4CC384Q26777929-6C5EAB83-BEFC-4E13-A6A3-6162A6D91FDEQ26829111-FC8CCC2C-F8F2-4D2C-B0F0-785A85F2018EQ27009466-3F70AA71-02AA-444A-A6F8-3C90A722ED8AQ27015029-0C87BF9E-AF8F-4C32-93EF-A821525CE6C8Q28073952-5C501B5C-0777-45CA-9927-46CC0F4D7BF6Q33664105-B239F9B5-2D66-42A3-A476-31A88BD5126BQ33746277-DE78AD58-20C2-400E-979F-AFAB6D2C81B9Q33908169-44E76D6F-9006-44BA-B244-A2E5595E885BQ33936763-346D12B5-D3D7-4DCA-8D48-17B2E8891F21Q34098196-C48DFD0E-94FF-419D-B8C0-083826670D97Q34173626-75099825-4960-4628-9366-75129C3DBDA5Q34186015-B94FD3AE-C397-4354-AFF3-60E7B4C5A95DQ34583231-B2DFE0B5-B66A-4AF6-9541-C807DE743E11Q35028750-8C62EC66-3DCC-4D1D-B642-4778C623A425Q35179985-53C29637-DF1F-4267-A360-FFEE7ADE3361Q36385052-EF437702-D7C9-4C52-9BE3-B55CAFD1B83BQ36452404-87BFDF31-45EB-488A-98A6-6F33712F60A4Q36933683-8AE028EA-928C-4953-AFFA-8571818DF4EBQ36938493-65FF4576-54F6-4399-A089-5BEB96CB0D76Q37008837-2CB3A75F-F20F-494A-B06C-C02952FB083DQ37120339-7D6CC2DD-B118-4AAB-8DCA-73A300810792Q37150745-BE52AB6F-26BD-476D-8345-DEAB6A186E21Q37164807-F5C32250-0D1E-445F-83B8-3BE105FA4A80Q37230665-BE35CDFB-102D-4421-80C9-A758DCC22C42Q37253331-4ECE7E78-6277-40AA-9DA3-C7BF9CBD08DEQ37264965-65C8FC51-382C-4172-8155-031A3F5CE2D4Q37681996-B79F627C-68F6-4FAD-A423-A4D0AC356F2DQ37709583-2EE9807D-C428-46CB-85C4-4ADD67223473Q38013238-81885B82-25BD-4AA0-8C44-C6EE9CE54223Q38223774-A9BD8894-092F-4A59-A8FE-8888712A4BA1Q38324480-78899065-6423-4EE8-9189-1224C2D64525Q38395012-3F746E18-8EF8-4364-91E6-231BDA6B037CQ38563981-8F3A775F-9359-4FFE-A4BC-9AADBA5DC739
P2860
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@ast
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@en
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@nl
type
label
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@ast
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@en
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@nl
prefLabel
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@ast
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@en
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@nl
P2093
P2860
P3181
P1476
The CB2 cannabinoid agonist AM ...... hen initiated at symptom onset
@en
P2093
Jennifer L Shoemaker
John P Crow
Kathryn A Seely
Paul L Prather
Ronald L Reed
P2860
P3181
P356
10.1111/J.1471-4159.2006.04346.X
P407
P577
2007-04-01T00:00:00Z